RENEPHRA  

Treatment of fluid overload and oedema  

OWNER

(See Profile)


Sector

Medical Device

Stage

Prototype

Funding needed

£400 000

Country

UK

PATIENTS WILL BE ABLE TO USE RENEPHRA’S device AT HOME BY THEMSELVES

safer than blood based approaches such as large doses of diuretics

92% of healthcare professionals (n=55) said that they are interested in using Renephra’s device

CENTRAL MANCHESTER NHS TRUST IS RENEPHRA INVESTOR AND SHAREHOLDER

Catapult Ventures and Deepbridge Capital are committed to investing £250k in this round

If you want to have more information or you want to review the project, you have to login or register
Contact the entrepreneur
Share your thoughts with other BioExperts

KEEP REVIEWING

©2023 BioExpert Network

About cookies

This website uses cookies to give you the best user experience. If you continue browsing you are giving your consent for the acceptance of those cookies and the acceptance of our cookies policy.

If you continue to browse and use this website you are agreeing to comply with and be bound by the following Terms of Use

ACEPTAR
Aviso de cookies

Log in with your credentials

or    

Forgot your details?

Create Account

Skip to toolbar